Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name: Ondansetron Hydrochloride Injection (Hospira, Inc.)

Product Code(s): PZ03381

Trade Name: Ondansetron Injection

Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use: Pharmaceutical product for the treatment of nausea and vomiting (antiemetic)

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

1.4. Emergency telephone number

Emergency Telephone: Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887
E-mail address: pfizer-MSDS@pfizer.com

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Not classified as hazardous

2.2. Label elements

Signal word: Not classified

Hazard statements: Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards: An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
Note:
This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.1 Substances

<table>
<thead>
<tr>
<th>Substance</th>
<th>Weight-%</th>
<th>REACH Registration Number</th>
<th>EC No</th>
<th>Classification according to Regulation (EC) No. 1272/2008 [CLP]</th>
<th>Specific concentration limit (SCL)</th>
<th>M-Factor</th>
<th>M-Factor (long-term)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hazardous</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ondansetron hydrochloride dihydrate</td>
<td>0.2</td>
<td>Not Listed</td>
<td></td>
<td>Acute Tox. 3 (H301) Aquatic. Acute 1 (H400) Aquatic. Chronic 1 (H410)</td>
<td>Not Listed</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td>Methyl-p-hydroxybenzoate</td>
<td>&gt;1</td>
<td>202-785-7</td>
<td></td>
<td>Aquatic Chronic 2 (H411)</td>
<td>No data available</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td>Propylparaben</td>
<td>&gt;1</td>
<td>202-307-7</td>
<td></td>
<td>Aquatic Chronic 3 (H412)</td>
<td>No data available</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Non-Hazardous</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td></td>
<td>*</td>
<td>231-791-2</td>
<td>No data available</td>
<td>Not Listed</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td></td>
<td>*</td>
<td>231-598-3</td>
<td>No data available</td>
<td>Not Listed</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td>Citric acid monohydrate</td>
<td></td>
<td>*</td>
<td>Not Listed</td>
<td>No data available</td>
<td>Not Listed</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td>Sodium Citrate</td>
<td></td>
<td>*</td>
<td>612-118-5</td>
<td>No data available</td>
<td>Not Listed</td>
<td>No data available</td>
<td>No data available</td>
</tr>
</tbody>
</table>

Full text of H- and EUH-phrases: see section 16

**Acute Toxicity Estimate**
No information available
SAFETY DATA SHEET

Product Name  Ondansetron Hydrochloride Injection (Hospira, Inc.)
Revision date  06-Dec-2021
Version  2.05

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Oral LD50</th>
<th>Dermal LD50</th>
<th>Inhalation LC50 - 4 hour - dust/mist - mg/L</th>
<th>Inhalation LC50 - 4 hour - vapor - mg/L</th>
<th>Inhalation LC50 - 4 hour - gas - ppm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water 7732-18-5</td>
<td>89838.9</td>
<td>No data available</td>
<td>No data available</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td>SODIUM CHLORIDE 7647-14-5</td>
<td>3000</td>
<td>10000</td>
<td>No data available</td>
<td>No data available</td>
<td>No data available</td>
</tr>
</tbody>
</table>

Additional information  * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation
Remove to fresh air. Seek immediate medical attention/advice.

Eye contact
Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.

Skin contact
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed
Note to physicians
None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media
Suitable Extinguishing Media  Water, dry powder or foam extinguishers are recommended.

5.2. Special hazards arising from the substance or mixture
Specific hazards arising from the chemical  Fine particles (such as dust and mists) may fuel fires/explosions.
Hazardous combustion products  Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters
Special protective equipment for fire-fighters  Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES
6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits Refer to available public information for specific member state Occupational Exposure Limits.

Ondansetron hydrochloride dihydrate
Pfizer OEL TWA-8 Hr: 10 µg/m³

SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latvia</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Russia</td>
<td>MAC: 5 mg/m³</td>
</tr>
</tbody>
</table>

Methyl-p-hydroxybenzoate

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russia</td>
<td>MAC: 4 mg/m³</td>
</tr>
</tbody>
</table>

Propylparaben

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russia</td>
<td>MAC: 10 mg/m³</td>
</tr>
</tbody>
</table>

SODIUM CHLORIDE
Pfizer Occupational Exposure Band (OEB):
OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

8.2. Exposure controls

Engineering controls
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls
No information available.

Personal protective equipment
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection
Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection
Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection
Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations
Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>Solution</td>
</tr>
<tr>
<td>Color</td>
<td>Colorless</td>
</tr>
<tr>
<td>Odor</td>
<td>No information available</td>
</tr>
<tr>
<td>Odor threshold</td>
<td>No information available</td>
</tr>
<tr>
<td>Molecular formula</td>
<td>Mixture</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>Mixture</td>
</tr>
<tr>
<td>pH</td>
<td>3.3 - 4.0</td>
</tr>
<tr>
<td>Melting point / freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling point / boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No information available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability Limit in Air</td>
<td></td>
</tr>
<tr>
<td>Upper flammability limit:</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower flammability limit:</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
</tbody>
</table>

PZ03381
Section 10: STABILITY AND REACTIVITY

10.1. Reactivity
Reactivity
No data available.

10.2. Chemical stability
Stability
Stable under normal conditions.

Explosion data
Sensitivity to Mechanical Impact
No data available.
Sensitivity to Static Discharge
No data available.

10.3. Possibility of hazardous reactions
Possibility of hazardous reactions
No information available.

10.4. Conditions to avoid
Conditions to avoid
Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials
Incompatible materials
As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products
Hazardous decomposition products
No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:
The information included in this section describes the potential hazards of the individual ingredients.

Short term
Active ingredient may be harmful if swallowed. May cause eye irritation (based on components).

Long Term:
May cause effects on central nervous system through prolonged or repeated exposure.

Known Clinical Effects:
Adverse effects associated with therapeutic use include headache, flushing, and constipation. May cause irregular heartbeat (cardiac arrhythmia), hypersensitivity reactions.

Acute Toxicity: (Species, Route, End Point, Dose)
SODIUM CHLORIDE
Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 4 g/kg
Rabbit Dermal LD 50 > 10 g/kg

Ondansetron hydrochloride dihydrate
Rat Oral LD50 95 mg/kg
Rat Para-periosteal LD50 20201 ug/kg
Dog Oral LD50 > 45 mg/kg

Methyl-p-hydroxybenzoate
Mouse Oral LD50 > 8 g/kg
Rat Oral LD 50 2100 mg/kg

Propylparaben
Mouse Oral LD 50 6332 mg/kg
Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Oral LD50</th>
<th>Dermal LD50</th>
<th>Inhalation LC50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>&gt; 90 mL/kg (Rat)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>= 3 g/kg (Rat)</td>
<td>&gt; 10000 mg/kg (Rabbit)</td>
<td>&gt; 42 mg/L (Rat) 1 h</td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE
Skin irritation Rabbit Mild
Eye irritation Rabbit Mild

Methyl-p-hydroxybenzoate
Skin irritation Rabbit Non-irritating
Eye irritation Rabbit Slight
Skin Sensitization Guinea Pig Negative

Citric acid monohydrate
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ondansetron hydrochloride dihydrate
7 Week(s) Rat Oral 160 mg/kg/day Maximally Tolerated Dose
18 Month(s) Rat No route specified 1 mg/kg/day NOAEL Central Nervous System, Liver
12 Month(s) Dog No route specified 12 mg/kg/day NOAEL Central Nervous System, Liver

Methyl-p-hydroxybenzoate
28 Day(s) Rat Oral 250 mg/kg/day NOAEL Gastrointestinal System, Spleen, Thymus

Propylparaben
3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system
4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ondansetron hydrochloride dihydrate
Reproductive & Fertility Rat Oral 15 mg/kg/day NOAEL Negative
Fertility and Embryonic Development Rat Intravenous 4 mg/kg/day NOAEL No effects at maximum dose
Fertility and Embryonic Development Rabbit Intravenous 4 mg/kg/day NOAEL No effects at maximum dose

Methyl-p-hydroxybenzoate
Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOEL Maternal toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ondansetron hydrochloride dihydrate
Bacterial Mutagenicity (Ames)  
Salmonella, E. coli  Negative

In Vitro  Chromosome Aberration  Human Lymphocytes  Negative

In Vivo  Chromosome Aberration  Bone marrow Mouse  Negative

Methyl-p-hydroxybenzoate

In Vivo  Dominant Lethal Assay  Rat  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ondansetron hydrochloride dihydrate

2 Year(s) Rat Oral 10 mg/kg/day NOAEL Not carcinogenic

2 Year(s) Mouse Oral 30 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties  No information available.

11.2.2. Other information

Other adverse effects  No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview  The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided. See aquatic toxicity data for individual components below:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ondansetron hydrochloride dihydrate

Selenastrum capricornutum (Green Alga) IC50 72 hours 0.87 mg/L

Daphnia magna (Water Flea) EC50 48 days 28 mg/L

Oncorhynchus mykiss (Rainbow Trout) EC50 96 hours 6.5 mg/L

Activated sludge IC50 3 Hours > 1000 mg/L

Ceriodaphnia dubia (Daphnids) NOEC 8 days 0.32 mg/L

Methyl-p-hydroxybenzoate

Oryzias latipes (Japanese Rice Fish) OECD LC50 96 hours 59.5 mg/L

Daphnia magna (Water Flea) ISO EC50 48 hours 11.2 mg/L

Aquatic Toxicity Comments  A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

12.2. Persistence and degradability

Persistence and degradability  .

Methyl-p-hydroxybenzoate

OECD Activated sludge Ultimate (CO2 Evolution) 89% After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation  No information available.

12.4. Mobility in soil
Mobility in soil

No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>PBT and vPvB assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE</td>
<td>The substance is not PBT / vPvB PBT assessment does not apply</td>
</tr>
<tr>
<td>Methyl-p-hydroxybenzoate</td>
<td>The substance is not PBT / vPvB</td>
</tr>
<tr>
<td>Citric acid monohydrate</td>
<td>The substance is not PBT / vPvB</td>
</tr>
<tr>
<td>Sodium Citrate</td>
<td>The substance is not PBT / vPvB PBT assessment does not apply</td>
</tr>
<tr>
<td>Propylparaben</td>
<td>The substance is not PBT / vPvB</td>
</tr>
</tbody>
</table>

12.6. Endocrine disrupting properties

Endocrine disrupting properties

No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

<table>
<thead>
<tr>
<th>CERCLA/SARA Section 313 de minimus %</th>
<th>Not Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>TSCA</td>
<td>Present</td>
</tr>
<tr>
<td>EINECS</td>
<td>231-791-2</td>
</tr>
<tr>
<td>AICS</td>
<td>Present</td>
</tr>
</tbody>
</table>

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %

Not Listed
California Proposition 65  Not Listed
TSCA  Present
EINECS  231-598-3
AICS  Present

Ondansetron hydrochloride dihydrate
CERCLA/SARA Section 313 de minimus %  Not Listed
California Proposition 65  Not Listed
EINECS  Not Listed

Methyl-p-hydroxybenzoate
CERCLA/SARA Section 313 de minimus %  Not Listed
California Proposition 65  Not Listed
TSCA  Present
EINECS  202-785-7
AICS  Present

Citric acid monohydrate
CERCLA/SARA Section 313 de minimus %  Not Listed
California Proposition 65  Not Listed
EINECS  Not Listed
AICS  Present

Sodium Citrate
CERCLA/SARA Section 313 de minimus %  Not Listed
California Proposition 65  Not Listed
EINECS  Not Listed
AICS  Present

Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)

Propylparaben
CERCLA/SARA Section 313 de minimus %  Not Listed
California Proposition 65  Not Listed
TSCA  Present
EINECS  202-307-7
AICS  Present

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>French RG number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE</td>
<td>RG 78</td>
<td></td>
</tr>
<tr>
<td>7647-14-5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:
This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants
Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009
Not applicable

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Plant protection products directive (91/414/EEC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE - 7647-14-5</td>
<td>Plant protection agent</td>
</tr>
</tbody>
</table>

Legend:

PZ03381
15.2. Chemical safety assessment
Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3
H301 - Toxic if swallowed H400 - Very toxic to aquatic life H410 - Very toxic to aquatic life with long lasting effects H411 - Toxic to aquatic life with long lasting effects H412 - Harmful to aquatic life with long lasting effects

Data Sources: 
Publicly available toxicity information. Safety data sheets for individual ingredients.

Reason for revision
Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

Revision date 06-Dec-2021

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.